|
| Press Releases |
|
 |
|
| Tuesday, December 26, 2017 |
|
|
Nanobiotix: 2017 review and 2018 expected milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. more info >> |
|
|
FDA approves Nanobiotix's first Immuno-Oncology trial |
| A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) more info >> |
|
| Monday, November 13, 2017 |
|
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA. more info >> |
|
| Friday, November 10, 2017 |
|
|
Nanobiotix provides update on the global development of its lead product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3. more info >> |
|
| Monday, October 23, 2017 |
|
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. more info >> |
|
| Friday, September 29, 2017 |
|
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease. more info >> |
|
| Friday, September 1, 2017 |
|
|
Nanobiotix half year results for the six months ended 30 June 2017 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. more info >> |
|
| Friday, June 16, 2017 |
|
|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA. more info >> |
|
| Tuesday, June 6, 2017 |
|
|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
東海国立大学機構と富士通、生成AIを用いた診療データの活用により治験候補患者の選定に貢献
May 23, 2025 10:30: JST
|
|
|
Highly-acclaimed Cybersecurity Solutions and SOC Service Capabilities
May 23, 2025 09:02 HKT/SGT
|
|
|
52TOYS即將赴港上市 打造IP玩具新標桿
May 23, 2025 07:59 HKT/SGT
|
|
|
52TOYS即将赴港上市 打造IP玩具新标杆
May 23, 2025 07:36 HKT/SGT
|
|
|
DCLI Drives Fleet Efficiencies with BlackBerry Radar Deployment Across 100,000 Chassis
May 22, 2025 19:56 HKT/SGT
|
|
|
DCLI 部署 BlackBerry Radar 技術涵蓋10萬個車架，提升車隊營運效率
May 22, 2025 19:56 HKT/SGT
|
|
|
DCLI 部署 BlackBerry Radar 技术覆盖10万个车架，提高车队运营效率
May 22, 2025 19:56 HKT/SGT
|
|
|
Media Professionals Explore Global Cooperation in Digital Age
May 22, 2025 16:30 HKT/SGT
|
|
|
ARYA RESOURCES LTD. (RBZ) Arya Expands Exploration Portfolio With 38,926-Acre Strategic Gold Claims Acquisition Adjacent to Ramp Gold Discovery in Saskatchewan, Canada
May 22, 2025 15:59 HKT/SGT
|
|
|
中信國際電訊CPC信息安全方案及SOC服務實力獲市場認可
May 22, 2025 15:54 HKT/SGT
|
|
|
GMG Approves AU$900k for Early Works for 10 Tonne per Annum Second Generation Technology Graphene Production Plant
May 22, 2025 15:29 HKT/SGT
|
|
|
中信国际电讯CPC信息安全方案及SOC服务实力获市场认可
May 22, 2025 15:17 HKT/SGT
|
|
|
トヨタグループ5社、AI・ソフトウェアの人財育成とイノベーションを加速
May 22, 2025 14:00: JST
|
|
|
Honda 二輪車の世界生産累計5億台を達成
May 22, 2025 14:00: JST
|
|
|
Founders Metals Expands Upper Antino; Hits 33.0 m of 3.50 g/t Gold
May 22, 2025 13:39 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
